PANX1 and neoplasm: Our study demonstrates that a Panx1 deletion cannot overcome the aggressive tumorigenic effect of Braf(V600E)/Pten(del) driver mutations, but it increases the tumor T‐cell infiltration with a preference in CD8+ cytotoxic T cells.